Commitments, contingencies and guarantees

 

		Less than 1 year				1 – 3 years				3 – 5 years				Greater than 5 years				Total
Operating leases		$	440			$	915			$	706			$	-			$	2,061

 

The Company has entered into various contracts with service providers with respect to the clinical development of APTO- and for the development plan of These contracts will result in future payments of up to million.

 

The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain.

 

Under the license agreement with CrystalGenomics, the Company has obligations for development milestones of million related to the initiation of Phase and pivotal clinical trials, and regulatory milestones totaling million. The Company also has an obligation to pay royalty payments on sales of commercialized product. The timing of any milestone or royalty payments that become due is yet determinable.

 

On the Company entered into a license agreement with CrystalGenomics to gain an exclusive license to CG- in China. The Company has potential future obligations of development milestones of million related to approval of an Investigational New Drug (“IND”) and to the initiation of Phase and pivotal clinical trials, and regulatory milestones totaling million. The Company also has an obligation to pay sales milestones and royalty payments on sales of commercialized product. The timing or likelihood of any milestone or royalty payments that become due is yet determinable.